MTAP and cancer: Currently, more than 10 Phase 1/2 trials are ongoing with PRMT5 inhibitors in a variety of cancer types, in some cases, utilizing MTAP loss for cohort selection (https://clinicaltrials.gov/ (accessed on 10 December 2023)).